The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
08
2018
accepted:
18
12
2018
entrez:
17
1
2019
pubmed:
17
1
2019
medline:
12
10
2019
Statut:
epublish
Résumé
In the late 1950s and early 1960s the drug Thalidomide was marketed across the world as a non-addictive tranquilizer. Despite being given to pregnant women as a safe treatment for morning sickness, Thalidomide caused serious damage to the unborn child. Much has been written about the drug and the birth defects it caused but evidence about the health of Thalidomide survivors as they age is limited. The aim of this study was to: explore the health and wellbeing UK Thalidomide survivors; document the health problems experienced by them as they reach their mid-50s; and examine the impacts on their health-related quality of life and employment. A health and wellbeing survey of 351 UK Thalidomide survivors, which gathered information about home and employment circumstances, recent health problems, and health related quality of life (using SF12 Health Survey). Overall analysis focused on descriptive statistics; the association between respondents' health related quality of life and original impairment was examined using Pearson Correlation; and a three step Hierarchical Regression was used to explore the influence of five factors which narrative responses suggested might be important. As Thalidomide survivors reach their mid-50's they are experiencing a wide range of secondary health problems, in particular musculoskeletal problems, and depression and anxiety, with multimorbidity a growing issue. These health problems are having a negative impact on their employment (two fifths are unable to work) and their physical health related quality of life, which is significantly poorer than the general population. Having lived relatively independent lives, many Thalidomide survivors are now having to adjust to growing disability. The study provides further evidence of the accumulative impact of disability over peoples' lifetimes and highlights the value of a life course perspective in understanding the complex experience of growing older with a disability.
Sections du résumé
BACKGROUND
In the late 1950s and early 1960s the drug Thalidomide was marketed across the world as a non-addictive tranquilizer. Despite being given to pregnant women as a safe treatment for morning sickness, Thalidomide caused serious damage to the unborn child. Much has been written about the drug and the birth defects it caused but evidence about the health of Thalidomide survivors as they age is limited.
AIM
The aim of this study was to: explore the health and wellbeing UK Thalidomide survivors; document the health problems experienced by them as they reach their mid-50s; and examine the impacts on their health-related quality of life and employment.
METHODS
A health and wellbeing survey of 351 UK Thalidomide survivors, which gathered information about home and employment circumstances, recent health problems, and health related quality of life (using SF12 Health Survey). Overall analysis focused on descriptive statistics; the association between respondents' health related quality of life and original impairment was examined using Pearson Correlation; and a three step Hierarchical Regression was used to explore the influence of five factors which narrative responses suggested might be important.
RESULTS
As Thalidomide survivors reach their mid-50's they are experiencing a wide range of secondary health problems, in particular musculoskeletal problems, and depression and anxiety, with multimorbidity a growing issue. These health problems are having a negative impact on their employment (two fifths are unable to work) and their physical health related quality of life, which is significantly poorer than the general population.
DISCUSSION
Having lived relatively independent lives, many Thalidomide survivors are now having to adjust to growing disability. The study provides further evidence of the accumulative impact of disability over peoples' lifetimes and highlights the value of a life course perspective in understanding the complex experience of growing older with a disability.
Identifiants
pubmed: 30650111
doi: 10.1371/journal.pone.0210222
pii: PONE-D-18-24307
pmc: PMC6334953
doi:
Substances chimiques
Hypnotics and Sedatives
0
Thalidomide
4Z8R6ORS6L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0210222Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Birth Defects Res A Clin Mol Teratol. 2015 Sep;103(9):787-93
pubmed: 26033770
Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
Soc Sci Med. 2006 Jul;63(2):525-39
pubmed: 16530905
Ann Rheum Dis. 2014 Jun;73(6):968-74
pubmed: 24665116
Spinal Cord. 2013 Dec;51(12):882-92
pubmed: 24126851
Int J Integr Care. 2012 Nov 16;12:e201
pubmed: 23593057
J Gerontol B Psychol Sci Soc Sci. 2017 Mar 1;72(2):290-299
pubmed: 27702838
Arch Phys Med Rehabil. 2004 Jul;85(7 Suppl 3):S68-73; quiz S74-5
pubmed: 15221734
Ann Fam Med. 2009 Jul-Aug;7(4):357-63
pubmed: 19597174
Disabil Health J. 2018 Apr;11(2):184-191
pubmed: 29109034
Disabil Health J. 2014 Jan;7(1 Suppl):S44-50
pubmed: 24456685
J Child Orthop. 2016 Dec;10(6):691-703
pubmed: 27854003
Acta Odontol Scand. 2008 Oct;66(5):300-6
pubmed: 18720052
Soc Sci Med. 2019 Jun;231:55-61
pubmed: 29580648
Disabil Health J. 2012 Apr;5(2):102-10
pubmed: 22429544
J Med Genet. 1992 Oct;29(10):716-23
pubmed: 1433232
PLoS One. 2016 May 13;11(5):e0155493
pubmed: 27175919